意大利托斯卡纳地区药物不良事件直接成本及预防可节省费用的模型分析
该研究通过系统综述纳入12项观察性研究,估算药物不良事件(ADE)平均成本为2471.46欧元(±1214.13),可预防概率为45%(±21)。结合托斯卡纳2016年自发报告数据模拟显示,每百万居民ADE支出为3,406,280.63欧元(95%CI 1,732,910.44-5,079,664.61),预防可节省1,532,760.25欧元(95%CI 779,776.1-2,285,750.60)。
要点
- ADE平均成本约2471欧元,可预防比例约45%
- 每百万居民ADE年支出约340万欧元,预防可节省约153万欧元
- 敏感性分析支持结果的稳健性
核心结论
- ADE对托斯卡纳医疗系统具有显著经济影响
- 预防ADE可带来重要成本节省
- 结果可能可推广至其他医疗系统
研究设计与样本
- 系统综述遵循PRISMA和MOOSE声明,检索MEDLINE和EMBASE 2006-2016年高收入国家住院ADE直接成本观察性研究
- 纳入12项观察性研究,估算可预防ADE平均概率和ADE平均成本(蒙特卡洛模拟)
- 结合意大利国家药物警戒网络2016年托斯卡纳自发报告数据,模拟ADE和可预防ADE成本,并进行三项敏感性分析
主要发现
- ADE平均成本为2471.46欧元(±1214.13)
- 可预防ADE平均概率为45%(±21)
- 托斯卡纳每百万居民ADE支出为3,406,280.63欧元(95%CI 1,732,910.44-5,079,664.61)
- 每百万居民潜在成本节省为1,532,760.25欧元(95%CI 779,776.1-2,285,750.60)
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adverse drug events (ADEs) may represent an important item of expenditure for healthcare systems and their prevention could be associated with a relevant cost saving. OBJECTIVE: The objective of this study was to simulate the annual economic burden for ADEs in Tuscany (Italy) and the potential cost savings related to avoidable ADEs. METHODS: A systematic review was performed, according to the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) statements, on observational studies published from 2006 to 2016 in MEDLINE and EMBASE, focusing on direct costs of ADEs in the inpatient setting from high-income countries. The mean probability of preventable ADEs was estimated over the included studies. The mean ADE cost was calculated by means of Monte Carlo simulation. We then extrapolated the spontaneous reports of ADEs in Tuscany, Italy in 2016 from the Italian National Pharmacovigilance Network (Rete Nazionale di Farmacovigilanza), and we assumed the same costs and preventability probability for these as obtained in the systematic review. Finally, we simulated the possible costs of ADEs and preventable ADEs in Tuscany. Three sensitivity analyses were also performed to test the robustness of the results. RESULTS: Of 11,936 articles initially selected, 12 observational studies were included. The estimated mean [± standard deviation (SD)] ADE cost was €2471.46 (± €1214.13). The mean (± SD) probability of preventable ADEs was 45% (± 21). The Tuscan expenditure for ADEs was €3,406,280.63 per million inhabitants (95% confidence interval (CI) 1,732,910.44-5,079,664.61) and the potential cost saving was €1,532,760.25 per million inhabitants (95% CI 779,776.1-2,285,750.60). Sensitivity analyses confirmed the robustness of the results. CONCLUSIONS: The present simulation showed that ADEs could have a relevant economic impact on the Tuscan healthcare system. In this setting, the prevention of ADEs would result in important cost savings. These results could be likely extended to other healthcare systems.
引用
- Convertino I, Salvadori S, Pecori A, et al. Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis. Drug Saf. 2019. PMID: 30276630. doi:10.1007/s40264-018-0737-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。